World Biosimilar Congress

 

Discover. Develop. Get to market.

15-17 October | Congress Centre Basel

 

 
1,500+
Attendees
600+
1-2-1 Meetings
350+
Speakers
90+
Exhibitors
4
Co-located events

 

BIOSIMILAR AGENDA AT A GLANCE

 

 

Day 1 – Tuesday 15th October 2019
Keynotes: European policy
Networking Break
Plenary roundtable session
Networking Lunch
WORKSHOP 1: Characterisation of a biosimilar drug Tudor Arvinte, Chairman, CEO, Therapeomic (CONFIRMED)
Track 1 Commercialisation Track 2 Development and Manufacturing of Biosimilars
Afternoon refreshments
Commercialisation Development and Manufacturing of Biosimilars
Chair’s end of day 1 remarks Chair’s end of day 1 remarks
Offsite Networking Drinks

 

 

Day 2 – Wednesday 16th October 2019
Keynotes: Biosimilars in the US
Networking Break
Track 1 Regulatory Challenges Track 2 Clinical Trials and Real-World Evidence
Networking Lunch
IP and Legal Considerations for Biosimilars Biosimilar Sustainability
Afternoon refreshments
Biosimilar Sustainability and the Future of Biosimilars
Chair’s closing remarks
End of Conference – Drinks Reception

 

SESSIONS YOU CAN'T MISS

 

The future of biosimilars in the US and European markets

• Importance of biosimilars: a key to sustainable healthcare future
• Differences between US and European markets: is the gap closing?
• Impact of biosimilars so far in Europe/US: the ongoing success story
• How to further improve the future of biosimilar access: incentivizing competition

Stefan Hendriks , Global Head, Biopharmaceuticals , Sandoz

Orphan drugs as biosimilars - is there a future?

• Orphan Biosimilar Clinical development -what needs to change?
• Do regulations support orphan Biosimilar development?

Barbara Valenta-Singer , Chief Medical Officer , Fresenius Kabi

Jonathan Underhill | Associate Director For Medicines Evidence | NICE » speaking at Festival of Biologics

Biosimilars: measuring uptake, supporting implementation, widening access

• An update on the current policy situation with regard to the use of biosimilars in the NHS
• How uptake is being measured in the NHS and variation being addressed
• Future plans to support implementation of biosimilar policy and guidance

Jonathan Underhill , Associate Director For Medicines Evidence , NICE

Adam Levysohn | Head Of Global Market Access Biogen Biosimilars Business Unit | Biogen » speaking at Festival of Biologics

Biosimilars in Europe after the 3 successful aTNF launches

• How the market developed since 2015
• Pivotal governmental initiatives
• Important learnings to secure sustainable biosimilars market

Adam Levysohn , Head Of Global Market Access Biogen Biosimilars Business Unit , Biogen

Dorthe Bartels | Strategic Adviser | Amgros » speaking at Festival of Biologics

The phenomenal uptake of biosimilars in Denmark. What’s the secret?

• Who are the stakeholders, what are their roles and how exactly did each of them contribute to the result?
• Is this only a success story or are there any clouds on the horizon?
• What can anybody learn from Denmark and what will prove more difficult to copy?
• Will the Danish market be sustainable in the coming years?

Dorthe Bartels , Strategic Adviser , Amgros

Steinar Madsen | Medical Director | Norwegian Medicines Agency, Norway » speaking at Festival of Biologics

Successes and future direction of biosimilars in Europe

• What biosimilars have done to sustain healthcare but what about sustainability of biosimilars?
• Do we need a change in direction?
• Vision moving forward

Steinar Madsen , Medical Director , Norwegian Medicines Agency, Norway

Sustaining and harmonising biosimilars through WHO international standards

• Concept of International Standardisation
• Recent developments in WHO International Standards for Biosimilar Medicines including monoclonal antibodies
• Future plans for WHO Standards for Biosimilars

Meenu Wadhwa , Section Leader For Cyotkines And Growth Factors Section , NIBSC

 

 

Sign Up for Event Updates

 

There are two parts to the Festival of Biologics: four conferences covering Antibodies, Immunotherapy, Biosimilars and Clinical Trials and an exhibition featuring solutions for pharma and biotech.

There is a registration fee to attend the conferences. To visit the exhibition is free.